Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028860 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
A Phase 2 study, sponsored by Tulane University Health Sciences Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00028860: Completed Phase 2 study, sponsored by Tulane University Health Sciences Center.
NCT00028860 is a Phase 2 study that has completed, run by Tulane University Health Sciences Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00028860, a Phase 2 study, has completed, sponsored by Tulane University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following surgery in treating patients who have urinary tract cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-10 |
| Est. Completion | 2004-10 |
| Phase | Phase 2 |
What the finished NCT00028860 record still lists
NCT00028860 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00028860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00028860 about?
NCT00028860 is a clinical study titled "Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following surgery in treating patients who h...
What is the current status of trial NCT00028860?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-10. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00028860?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00028860?
This trial is sponsored by Tulane University Health Sciences Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia